Radiotherapy Combined with Pyrotinib Plus Capecitabine in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases: A Single-Arm, Exploratory Trial

被引：0
|
作者：
Wang, J. [1 ]
Wang, P. [2 ]
You, J. [2 ]
Wang, X. [3 ]
Hou, H. [2 ]
Zhang, B. [2 ]
Chai, Y. [2 ]
Cao, Y. [2 ]
机构：
[1] Tianjin Med Univ Canc Inst & Hosp, Dept Radiat Oncol, Natl Clin Res Ctr Canc, Key Lab Canc Prevent Therapy, Tianjin, Peoples R China
[2] Tianjin Med Univ Canc Inst & Hosp, Dept Radiat Oncol, Natl Clin Res Ctr Canc, Key Lab Canc Prevent Therapy, Tianjin, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Dept Breast Oncol, Natl Clin Res Ctr Canc, Key Lab Canc Prevent Therapy, Tianjin, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 120卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2625
引用
收藏
页码：E283 / E284
页数：2
相关论文
共 50 条
  • [21] Lapatinib Plus Capecitabine Resolved Human Epidermal Growth Factor Receptor 2-Positive Brain Metastases
    Glueck, Stefan
    Castrellon, Aurelio
    AMERICAN JOURNAL OF THERAPEUTICS, 2009, 16 (06) : 585 - 590
  • [22] Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
    Rupert Bartsch
    Anna Sophie Berghoff
    Julia Furtner
    Maximilian Marhold
    Elisabeth Sophie Bergen
    Sophie Roider-Schur
    Angelika Martina Starzer
    Heidrun Forstner
    Beate Rottenmanner
    Karin Dieckmann
    Zsuzsanna Bago-Horvath
    Helmuth Haslacher
    Georg Widhalm
    Aysegül Ilhan-Mutlu
    Christoph Minichsdorfer
    Thorsten Fuereder
    Thomas Szekeres
    Leopold Oehler
    Birgit Gruenberger
    Christian F. Singer
    Ansgar Weltermann
    Rainer Puhr
    Matthias Preusser
    Nature Medicine, 2022, 28 : 1840 - 1847
  • [23] Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
    Bartsch, Rupert
    Berghoff, Anna Sophie
    Furtner, Julia
    Marhold, Maximilian
    Bergen, Elisabeth Sophie
    Roider-Schur, Sophie
    Starzer, Angelika Martina
    Forstner, Heidrun
    Rottenmanner, Beate
    Dieckmann, Karin
    Bago-Horvath, Zsuzsanna
    Haslacher, Helmuth
    Widhalm, Georg
    Ilhan-Mutlu, Aysegul
    Minichsdorfer, Christoph
    Fuereder, Thorsten
    Szekeres, Thomas
    Oehler, Leopold
    Gruenberger, Birgit
    Singer, Christian F.
    Weltermann, Ansgar
    Puhr, Rainer
    Preusser, Matthias
    NATURE MEDICINE, 2022, 28 (09) : 1840 - +
  • [24] Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial
    Hu, Zhe-Yu
    Yan, Min
    Xiong, Huihua
    Ran, Li
    Zhong, Jincai
    Luo, Ting
    Sun, Tao
    Xie, Ning
    Liu, Liping
    Yang, Xiaohong
    Xiao, Huawu
    Li, Jing
    Liu, Binliang
    Ouyang, Quchang
    BMC MEDICINE, 2023, 21 (01)
  • [25] Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial
    Zhe-Yu Hu
    Min Yan
    Huihua Xiong
    Li Ran
    Jincai Zhong
    Ting Luo
    Tao Sun
    Ning Xie
    Liping Liu
    Xiaohong Yang
    Huawu Xiao
    Jing Li
    Binliang Liu
    Quchang Ouyang
    BMC Medicine, 21
  • [26] Management of Brain Metastases from Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer
    McGranahan, Tresa M.
    Bonm, Alipi, V
    Specht, Jennifer M.
    Venur, Vyshak
    Lo, Simon S.
    CANCERS, 2022, 14 (20)
  • [27] Combined pyrotinib and fulvestrant for hormone receptor-positive and HER2-positive metastatic breast cancer: A multicenter, single-arm, phase II trial
    Zhao, Jianli
    Yu, Yunfang
    Ren, Wei
    Ding, Linxiaoxiao
    Chen, Yongjian
    Yuan, Peng
    Yue, Jian
    Yang, Yaping
    Zou, Guorong
    Chen, Tao
    Chai, Jie
    Zhang, Li
    Wu, Wenjing
    Zeng, Yinduo
    Gui, Xiujuan
    Cai, Yangyang
    Luo, Simin
    Yuan, Zhongyu
    Zhang, Kang
    Yao, Herui
    Wang, Ying
    MEDCOMM, 2025, 6 (01):
  • [28] Efficacy and Safety of Radiotherapy Combined with Pyrotinib in the Treatment of HER2-Positive Breast Cancer with Brain Metastases
    Huang, Jie
    Zhu, Wenqiang
    Duan, Qiangzhi
    Zhu, Chaomang
    Shi, Xueling
    Zhao, Hongyu
    Cai, Peng
    Li, Duojie
    BREAST CANCER-TARGETS AND THERAPY, 2023, 15 : 841 - 853
  • [29] TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases
    Freedman, Rachel A.
    Gelman, Rebecca S.
    Anders, Carey K.
    Melisko, Michelle E.
    Parsons, Heather A.
    Cropp, Anne M.
    Silvestri, Kelly
    Cotter, Christine M.
    Componeschi, Kathryn P.
    Marte, Juan M.
    Connolly, Roisin M.
    Moy, Beverly
    Van Poznak, Catherine H.
    Blackwell, Kimberly L.
    Puhalla, Shannon L.
    Jankowitz, Rachel C.
    Smith, Karen L.
    Ibrahim, Nuhad
    Moynihan, Timothy J.
    O'Sullivan, Ciara C.
    Nangia, Julie
    Niravath, Polly
    Tung, Nadine
    Pohlmann, Paula R.
    Burns, Robyn
    Rimawi, Mothaffar F.
    Krop, Ian E.
    Wolff, Antonio C.
    Winer, Eric P.
    Lin, Nancy U.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (13) : 1081 - +
  • [30] Tucatinib Plus Trastuzumab and Capecitabine for ERBB2 (HER2)-Positive Metastatic Breast Cancer With Brain Metastases
    Mo, Dun-Chang
    Luo, Peng-Hui
    Huang, Jian-Feng
    JAMA ONCOLOGY, 2023, 9 (07) : 1008 - 1009
12345